SCHEMBL1792607

SCHEMBL1792607

Cc1cc(CNC(=O)c2ccc3c(c2)CCN(C2=CC=C2)CC3)nn1C

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.48
SLC5A7 Q9GZV3 1/20 0.46
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 4/20 0.42
HTT P42858 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX15 P16050 1/20 0.41
CYP3A4 P08684 3/20 0.39
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1788400 0.87 HDAC6 (0.40) ROCK2NPC1RAB9AALDH1A1HTT
SCHEMBL1786312 0.85 RAB9A (0.42) ROCK2SLC5A7NPC1RAB9AALDH1A1
SCHEMBL1787686 0.85 NAMPT (0.49) ROCK2ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL1787247 0.84 KMT2A (0.37) ROCK2CYP3A4KMT2A
SCHEMBL1789970 0.83 ROCK2 (0.49) ROCK2SMN1; SMN2USP2KMT2A
SCHEMBL1789608 0.83 NAMPT (0.49) ROCK2NPC1RAB9AALDH1A1LMNA
SCHEMBL1787084 0.82 HPGDS (0.43) ROCK2NPC1RAB9AKDM4EKMT2A
SCHEMBL1787944 0.82 MAPT (0.41) ROCK2ALDH1A1KDM4EALOX15KMT2A
SCHEMBL1789071 0.82 NPC1 (0.41) ROCK2NPC1RAB9AALDH1A1HTT
SCHEMBL1787644 0.82 ALDH1A1 (0.53) NPC1RAB9AALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 ROCK2 2377/4885SLC5A7 557/4885NPC1 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.